Abstract
Background Widespread use of retinal optical coherence tomography angiography (OCT-A) imaging in population-based studies requires methodological and analytical consensus to ensure reproducible and accurate results.
Objective Development of a consensus framework for assessment of OCT-A image quality and working with OCT-A-derived variables in population studies.
Methods Criteria for image quality were developed for fovea-centered, 3×3-mm OCT-A images acquired with three commercially available devices. Inter- and intragrader agreements for overall image quality, vessel density (VD) and foveal avascular zone (FAZ) area were evaluated among five graders (% agreement). Intergrader agreement was validated on 6×6-mm OCT-A images. Recommendations for grading and use of OCT-A images in epidemiological studies were developed.
Results Mean intergrader agreements for overall “Unusable”, “Usable”, and “Excellent” 3×3-mm OCT-A image quality (52 images) were 82.3%, 70.8%, and 87.1%; for “Unusable” VD and FAZ area agreements were 80.0% and 81.9%, respectively. Mean intragrader agreements for overall “Unusable”, “Usable” and “Excellent” 3×3-mm OCT-A image quality (27 images) were 91.1%, 82.2%, and 81.9%; agreements for “Unusable” VD and FAZ area were 89.6%; and 92.6%, respectively. Mean intergrader agreements for assessment of overall “Unusable”, “Usable” and “Excellent” 6×6-mm OCT-A images (21 images) were 73.3 %, 57.1% and 83.8%, agreements for “Unusable” VD and FAZ area were 60.0 % and 84.8 %, respectively. Three analytic scenarios were developed to account for common types of bias related to suboptimal OCT-A image quality and ocular comorbidities.
Conclusion These recommendations provide a framework for working with OCT-A imaging in population studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding Sources The Maastricht Study This study was supported by the European Regional Development Fund via OP-Zuid, the Province of Limburg, the Dutch Ministry of Economic Affairs (grant 31O.041), Stichting De Weijerhorst (Maastricht, the Netherlands), the Pearl String Initiative Diabetes (Amsterdam, the Netherlands), the Cardiovascular Center (CVC, Maastricht, the Netherlands), CARIM School for Cardiovascular Diseases (Maastricht, the Netherlands), CAPHRI School for Public Health and Primary Care (Maastricht, the Netherlands), NUTRIM School for Nutrition and Translational Research in Metabolism (Maastricht, the Netherlands), Stichting Annadal (Maastricht, the Netherlands), Health Foundation Limburg (Maastricht, the Netherlands), Perimed (Jarfalla, Sweden), and by unrestricted grants from Janssen-Cilag B.V. (Tilburg, the Netherlands), Novo Nordisk Farma B.V. (Alphen aan den Rijn, the Netherlands), and Sanofi-Aventis Netherlands B.V. (Gouda, the Netherlands). Rotterdam Study The Rotterdam Study is supported by the Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Oogfonds, Stichting voor Ooglijders, Stichting voor Blindenhulp, Henkes stichting, Rotterrdams Stichting voor Blindenbelangen, and Landelijke Stichting voor Blinden en Slechtzienden. Additional support was given by the Erasmus Medical Center, Erasmus University, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. Rhineland Study The Rhineland Study (P.I. Breteler) is primarily supported by DZNE core funding. The DZNE is funded by the Federal Ministry of Education and Research (BMBF) and the Ministry of Culture and Science of the German State of North Rhine-Westphalia. Framingham Heart Study National Institutes of Health R01AG066524 (AHK, SS), FHS contract 75N92019D00031, and P30AG066546. SIGNATR This work was supported by: National Eye Institute under R01 EY027134 and Government of India Department of Biotechnology under Grant BT/PR22701/MED/15/166/2016.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of all institutions (Maastricht University, Rotterdam University, Framingham Heart Study, Rhineland Study, and Rothschild Hospital) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos